Filing 2020 Q4 compared to 2020 Q3 - Restatement by default. Changes are calculated vs the previous SEC filing.
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
Person Signing this Report on Behalf of Reporting Manager:
Name
Title
City, State
Date
David L. Stepp
Authorized Signatory
Palo Alto, California
12 Feb 2021
The securities of 10X Genomics Inc. reported in the table below exclude 5,368,880 shares of Class B Common Stock held by Venrock Associates VI, LP. The institutional investment manager of this report included these shares of Class B Common Stock in its previous Schedule 13F.
We use cookies and similar technologies to provide certain features, enhance
the user experience and deliver content that is relevant to your interests.
Depending on their purpose, analysis and marketing cookies may be used in
addition to technically necessary cookies. By clicking on "Agree and
continue", you declare your consent to the use of the aforementioned cookies.
Here
you can make detailed settings or revoke your consent (in part if necessary)
with effect for the future. For further information, please refer to our
Privacy Policy
.